Funding
None of our work would be possible without the support we receive from our generous funders past and present. Currently, our work receives funding from:
ERC Advanced Grant
BorderControl: Regaining control of cancer at biological borders (2024-2029)
In this project we will identify the ligand-receptor pairs situated at critical cancer dissemination borders and investigate their contribution to the metastatic cascade using innovative approaches.
This project is funded by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 101142305).
Worldwide Cancer Research (WWCR)
Microenvironmental containment of tumours through paracrine
secretion (2023-2025)
We discovered that mammary gland adipocytes secrete a potent
anti-invasive cue, insulin-like growth factor binding protein 2
(IGFBP2), which efficiently blocks triple-negative breast cancer
cell invasion in vitro and in vivo. In this project, we aim to
uncover the molecular pathways underpinning IGFBP2 anti-invasive
activity in the mammary gland.
Jane Ja Aatos Erkon Säätiö
Cancer metastasis – new biological paradigms as drug targets (2023 –
2027)
In this project, we aim to explore the mechanisms of cancer-cell
intravasation and extravasation.
Juseslius Foundation
Scaffolding Oncogenic Signaling – identification of clinically
relevant signaling integrators (2023-2026)
Recently, we uncovered a scaffolding protein as a key regulator of
oncogenic KRAS signaling in PDAC with important clinical
implications. Now, we aim to gain a deeper understanding of its
function in NSCLC and CRC and assess its role beyond KRAS.
The Academy of Finland
BarrierForce Centre of Excellence - Biological Barrier Mechanics and
Disease: From molecular-scale to tissue-level understanding of
signal integration and forces (2022-2029)
Research Project - Adhesion dynamics and mechanobiological pathways
as determinants of oncogenic properties (2019-2023)
Cancer Society of Finland
Receptor sorting and cytoskeletal regulation in breast cancer (2020-2023)
Other partners
The Finnish Cancer Institute
The European Research Council
European Molecular Biology Organization
